The data suggest that, while combined targeting of FAK and MEK with small molecules can produce spikes of strong synergy (e.g., E17 cells, Figure 5A–D), in 29% of GBM stem cell lines (4/14) tested in this study, the general trend suggests potent additivity (7/14). Here, PTK2 is linked to glioblastoma.